BioSpace News Archive

Apollo Endosurgery, Inc., a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced highlights from Digestive Disease Week 2021 which was held May 21-23.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has accepted a GalXC™ RNAi candidate for advancement under the existing agreement between the companies

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders n

ImpriMed, Inc., a leading veterinary precision medicine biotech startup announced the launching of their most advanced precision medicine service for canine hematopoietic cancers - ImpriMed Chemo Response Prediction and ImpriMed Immunophenotyping for Canine Lymphoma.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has received a notice of allowance from the United States Patent and Trademark Office for an enhanced platform technology that aims to improve the potency of RNAi therapeutics by increasing delivery of siRNA to target cells.

Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry development veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing.

Transaction proceeds will be used to fund the further development of the MosaiQ platform beyond the Donor Lab and the commercial launch of MosaiQ

A new research paper, funded by the Reboot Foundation, outlines effective strategies for combating misinformation campaigns, particularly around the COVID-19 pandemic.

Results from Phase 1 study of novel GPRC5DxCD3 T-cell redirecting bispecific antibody demonstrate promising clinical activity and support recommended Phase 2 dose

HeMo Bioengineering Ltd (“HeMo”), a Singapore -based medical device company with a focus on treating stroke patients, is pleased to announce that its Afentta™ intracranial thrombectomy aspiration catheter has received pre-market approval